ANEB - Anebulo Pharmaceuticals

-

$undefined

N/A

(N/A)

Anebulo Pharmaceuticals NASDAQ:ANEB Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.

Location: | Website: www.anebulo.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

47.48M

Cash

3.094M

Avg Qtr Burn

-2.023M

Short % of Float

0.46%

Insider Ownership

64.22%

Institutional Own.

28.18%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.